[1] SIMONS F E R.Advances in H1-antihistamines[J] . N Engl J Med， 2004， 351(21) ： 2203-2217. [2] DOVE S， ELZ S， SEIFERT R， et al. Structure-activity relationships of histamine H2 receptor ligands[J] . Mini Rev Med Chem， 2004， 4(9) ： 941-954. [3] STARK H， KATHMANN M， SCHLICKER E， et al. Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists[J] . Mini Rev Med Chem， 2004， 4(9) ： 965-977. [4] DE ESCH I J， BELZAR K J. Histamine H3 receptor agonists[J] . Mini Rev Med Chem， 2004， 4(9)：955-963. [5] VACONDIO F， MOR M， SILVA C， et al. Imidazole H3-antagonists： relationship between structure and ex vivo binding to rat brain H3-receptors[J] . Eur J Pharm Sci， 2004， 23(1) ： 89-98. [6] WITKIN J M， NELSON D L. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system[J] . Pharmacol Ther， 2004， 103(1) ： 1-20. [7] LEURS R， BAKKER R A， TIMMERMAN H， et al. The histamine H3 receptor： from gene cloning to H3 receptor drugs[J] . Nat Rev Drug Discovery， 2005， 4(2) ： 107-120. [8] JI R Y. The histamine H3-receptor ligands： potential therapeutic uses[J] . Pharm Care Res (药学服务与研究) ， 2004， 4(3) ： 183-187. [9] WELLENDORPH P， GOODMAN M W， BURSTEIN E S， et al. Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor[J] . Neuropharmacology， 2002， 42(7) ： 929-940. [10] KRAUSE M， ROULEAU A， STARK H， et al. Synthesis， X-ray crystallography， and pharmacokinetics of novel azomethine prodrugs of ?-alpha-methylhistamine： highly potent and selective histamine H3 receptor agonists[J] . J Med Chem， 1995，38(20): 4070-4079. [11] KITBUNNADAJ R， ZUIDERVELD O P， DE ESCH I J， et al. Synthesis and structure-activity relationships of conformationally constrained histamine H3 receptor agonists[J] . J Med Chem， 2003， 46(25)： 5445-5457. [12] KITBUNNADAJ R， ZUIDERVELD O P， CHRISTOPHE B， et al. Identification of 4-[1H-imidazol-4(5)-ylmethyl] pyridine (immethridine) as a novel， potent， and highly selective histamine H3 receptor agonist[J] . J Med Chem， 2004， 47(10) ： 2414-2417. [13] KITBUNNADAJ R， HASHIMOTO T， POLI E， et al. N-substituted piperidinyl alkyl imidazoles： discovery of methimepip as a potent and selective histamine H3 receptor agonist[J] . J Med Chem， 2005， 48(6) ： 2100-2107. [14] NAKAYA M， FUKUSHIMA Y， TAKEUCHI N， et al. Nasal allergic response mediated by histamine H3 receptors in murine allergic rhinitis[J] . Laryngoscope， 2005， 115(10) ： 1778-1784. [15] HANCOCK A A， BENNANI Y L， BUSH E N， et al. Antiobesity effects of A-331440， a novel non-imidazole histamine H3 receptor antagonist[J] . Eur J Pharmacol， 2004， 487(1-3) ： 183-197. [16] MOR M， BORDI F， SILVA C， et al. Synthesis， biological activity， QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists[J] .Bioorg Med Chem， 2004， 12(4) ： 663-674. [17] GRASSMANN S， APELT J， SIPPL W， et al. Histamine N-methyltransferase potencies and histamine hH3 receptor affinities[J] . Bioorg Med Chem， 2003， 11(10) ： 2163-2174. [18] BERTINARIA M， STILO A D， TOSCO P， et al. [3-(1H-Imidazol-4-yl)propyl] guanidines containing furoxan moieties： a New class of H3-antagonists endowed with NO-donor properties[J] . Bioorg Med Chem， 2003， 11(7) ： 1197-1205. [19] TOSCO P， BERTINARIA M， STILO A D， et al. Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives[J] . Bioorg Med Chem， 2005，13(15) ：4750-4759. [20] TOSCO P， BERTINARIA M， STILO A D， et al. Non-imidazole histamine NO-donor H3-antagonists[J] . Farmaco， 2005， 60(6-7) ： 507-512. [21] WALCZYNSKI K， ZUIDERVELD O P， TIMMERMAN H. Non-imidazole histamine H3 ligands. Part III. New 4-N-propylpiperazines as non-imidazole histamine H3-antagonists[J] . Eur J Med Chem， 2005， 40(1) ： 15-23. [22] LAZEWSKA D， KIEC KONONOWICZ K， ELZ S， et al. Piperidine-containing histamine H3 receptor antagonists of the carbamateseries： the alkyl derivatives[J] . Pharmazie， 2005， 60(6) ： 403-410. [23] ESBENSHADE T A， FOX G B， KRUEGER K M ， et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl] ethyl}-benzofuraN-5-yl)benzonitrile] ： I. Potent and selective histamine H3 receptor antagonist with drug-like properties[J] . J Pharmacol Exp Ther， 2005， 313(1) ： 165-175. [24] GFESSER G A， FAGHIH R， BENNANI Y L， et al. Structure-activity relationships of arylbenzofuran H3 receptor antagonists[J] . Bioorg Med Chem Lett ， 2005， 15(10) ：2559-2563. [25] COWART M， FAGHIH R， CURTIS M P， et al. 4-(2-[2-(2?-methylpyrrolidin-1-yl) ethyl] benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention[J] . J Med Chem， 2005， 48(1) ： 38-55. [26] DVORAK C A， APODACA R， BARBIER A J， et al. 4-Phenoxypiperidines： potent， conformationally restricted， non-imidazole histamine H3 antagonists[J] . J Med Chem， 2005， 48(6) ： 2229-2238. [27] ZARAGOZA F， STEPHENSEN H， PESCHKE B， et al. 2-(4-Alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists[J] . J Med Chem， 2005， 48(1) ：306-311. [28] APELT J， GRASSMANN S， LIGNEAU X， et al. Search for histamine H3 receptor antagonists with combined inhibitory potency at Ntau-methyltransferase： ether derivatives[J] . Pharmazie， 2005， 60(2) ： 97-106. [29] AKHTAR M， PILLAI K K， VOHORA D. Effect of thioperamide on modified forced swimming test-induced oxidative stress in mice[J] . Basic Clin Pharmacol Toxicol， 2005， 97(4) ： 218-221. [30] KOMATER V A， BUCKLEY M J， BROWMAN K E， et al. Effects of histamine H3 receptor antagonists in two models of spatial learning[J] . Behav Brain Res， 2005， 159(2) ： 295-300.